



MAIN PROGRAM

13th World Congress on Itch

October 12-14, 2025

Congress Centrum Heidelberg, Germany



www.wci25.com



International Forum for the Study of Itch

AN INFUSION OF RELIEF FROM CKD-ASSOCIATED PRURITUS¹



Kapruvia[®] (difelikefalin) Abbreviated Prescribing Information.

Please refer to full Summary of Product Characteristics before prescribing.

Active ingredient: One vial of 1 mL contains 50 micrograms difelikefalin (as acetate). **Presentation:** Clear, colourless solution for injection, free from particles (pH 4.5). **Indication:** Treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis. **Dosage and Administration:** Difelikefalin is administered 3 times per week by intravenous bolus injection into the venous line of the dialysis circuit at the end of the haemodialysis treatment during rinse-back or after rinse-back. The recommended dose of difelikefalin is 0.5 micrograms/kg dry body weight (i.e., the target postdialysis weight). **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Special warning and precautions:** **Hyperkalaemia:** In the placebo-controlled clinical studies a numerically higher rate of adverse events of hyperkalaemia was reported for the difelikefalin treated patients compared to placebo. No causal relationship was established. Frequent monitoring of potassium levels is recommended. **Cardiac failure and atrial fibrillation:** Difelikefalin has not been studied in patients with New York Heart Association class IV heart failure. In the pivotal clinical studies a small numerical imbalance of cardiac failure and atrial fibrillation events was observed in the difelikefalin treated patients compared to placebo, in particular among patients with a medical history of atrial fibrillation who discontinued or missed their atrial fibrillation treatment. No causal relationship was established. **Patients with impaired blood-brain barrier:** Patients with clinically important disruptions to the BBB (e.g., primary brain malignancies, CNS metastases or other inflammatory conditions, active multiple sclerosis, advanced Alzheimer's disease) may be at risk for difelikefalin entry into the CNS. Kapruvia should be prescribed with caution in such patients taking into account their individual benefit-risk balance with observation for potential CNS effects. **Dizziness and somnolence:** Dizziness and somnolence have occurred in patients taking difelikefalin and may subside over time with continued treatment. Concomitant use of sedating antihistamines, opioid analgesics or other CNS depressants may increase the likelihood of these adverse reactions and should be used with caution during treatment with difelikefalin. Compared to placebo, the incidence of somnolence was higher in difelikefalin treated subjects 65 years of age and older than in difelikefalin treated subjects less than 65 years of age. There are no data with respect to use of Kapruvia in pregnancy or breastfeeding. **Undesirable effects:** Common ($\geq 1/100$ to $< 1/10$): Somnolence, Paraesthesia; Uncommon ($\geq 1/1,000$ to $< 1/100$): Mental status changes, Dizziness, Headache, Vomiting, Nausea, Diarrhoea. Please consult the full SmPC in relation to other undesirable effects. **MA number:** EU/1/22/1643/001, EU/1/22/1643/002. **Date of Authorisation in EU:** 25/04/2022. **MA Holder:** Vifor Fresenius Medical Care Renal Pharma France, 100-101 Terrasse Boieldieu, Tour Franklin La Défense 8, 92042 Paris La Défense Cedex, France. **Date of revision:** 10/2024 **Prescription Only Medicine**

KAPRUVIA[®] is indicated for use in adult, in-center haemodialysis patients suffering from moderate-to-severe CKD-associated Pruritus¹

1. KAPRUVIA[®] Summary of Product Characteristics, Date of authorization: 25.04.2022; Last updated: 14.10.2024.

Kapruvia[®] (difelikefalin) is approved in the European Union, Iceland, Norway, Switzerland and the United Kingdom. Best efforts have been undertaken to ensure compliance with EFPIA Code and the EU SmPC. The SmPC may vary from country to country; before prescribing, always refer to the applicable local SmPC.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should also be reported to CSL Vifor at safety@viforpharma.com

KAPRUVIA[®]
German SmPC



HQ-DFK-2500110 | July 2025

Table of Contents

Welcome	4
Organizing Committee	6
General Info	7
Program	8
Sunday 12 October 2025	9
Monday 13 October 2025	10
Tuesday 14 October 2025	16
Sponsors	23



Dear Colleagues and Friends,

we are very pleased to announce the 13th World Congress on Itch (WCI). After a superb and very successful meeting in Miami, USA in November 2023 **we warmly invite you to our meeting in Heidelberg in 2025.**

The WCI is a biennial meeting of the International Forum of the Study of Itch (IFSI). IFSI is a lively multidisciplinary international society of clinicians and researchers dedicated to advancing itch research, from basic science to new drug development. Thus, it is the only society focussed on itch with a global representation of research and clinical experts. The mission of IFSI is accordingly to present an exciting and inspiring program with excellent networking opportunities. **IFSI was founded in 2005, so we can celebrate the society's 20th birthday together in 2025.**

We are witnessing exciting developments in the field that include breathtaking therapeutic advances for our patients and breakthrough developments in basic research on molecular and cellular level. The scientific program of the 13th World Congress on Itch (WCI) will focus on these exciting aspects of itch, chronic pruritus and prurigo, including genetics, molecular mechanisms, pathophysiology, clinics, diagnostics and therapy. The Young Investigator Council (YIC) and the Special Interest Groups (SIGs) of IFSI will contribute to the program with focussed

session. Again, we will have the honorary Bernhard and Kuraishi lectures and are excited to announce that Sarah Ross (USA) and Andreas Kremer (Switzerland) are the honored speakers this time.

We are looking forward to an excellent meeting with scientists and clinicians from different continents and countries around the world and sharing new and exciting results from the itch research. Heidelberg University was founded in 1386 and is the oldest university in today's Germany. It is one of Europe's most research-intensive institutions. This spirit and the wonderful city of Heidelberg will add to the pleasure of the meeting and will provide unforgettable memories beyond the science. We will make sure to keep up the optimism and atmosphere of collaboration that characterized our last meeting 2023 in Miami and – as some of you may remember – in Heidelberg that was the venue of the 3rd IFSI meeting in September 2005: So, 20 years later, we will also connect to the early adventurous spirit of this meeting.

Welcome to Heidelberg!

Elke Weisshaar, Martin Schmelz, Sonja Ständer,
Thomas Mettang



13th World Congress on Itch (WCI)

Heidelberg, October 12-14, 2025

Organizing Committee

Prof. Dr. med. Elke Weisshaar

(Congress President)
Division of Occupational Dermatology
Department of Dermatology
University Hospital
Ruprecht-Karls-University Heidelberg
Germany

Prof. Dr. med. Dr. h.c. Sonja Ständer

Section for Pruritus Medicine
and Department of
Dermatology
Center for Chronic Pruritus
University Hospital Münster (UKM)
Germany

Prof. Dr. med. Thomas Mettang

Chief Physician
KfH Kidney Center Wiesbaden
Germany

Prof. Dr. med. Martin Schmelz

Department of Experimental Pain Research
Medical Faculty Mannheim
Heidelberg University
Germany

General Info

Board of Directors

Brian Kim, MD, New York, USA
Matthias Ringkamp, MD, Baltimore, USA
Christina Schut, Psychologist, Gießen, Germany
Sonja Ständer, MD, Münster, Germany
Jacek Szepietowski, MD, Wroclaw, Poland
Mitsutoshi Tominaga, MD, Chiba, Japan
Elke Weisshaar, MD, Heidelberg, Germany
Gil Yosipovitch, MD, Miami, USA
Leigh Nattkemper, PhD, Miami, USA

Prize committee

Martin Schmelz, Elke Weisshaar, Ethan Lerner,
Hiroyuki Murota, Alan Fleischer

Conference Venue

Congress Centrum Heidelberg
Czernyring 20
69115 Heidelberg

Partner Hotel

Atlantic Hotel
Europaplatz 1
69115 Heidelberg

Congress organisation

ECM Expo & Conference Management
GmbH
Alexander Meurer
An der Rechtschule 1-3
50667 Köln
Mail: am@ecm-koeln.com
Fon: +49 221 91395920
Fax: +49 221 91395928
Mobil: +49 1511 4657729



13th World Congress on Itch

October 12-14, 2025
Congress Centrum Heidelberg
Germany

Program



Sunday 12 October 2025

03.00 – 05.00 PM	IFSI SIG GLOBAL DAY Saal 2 What is important for patients? Chair: Sonja Ständer, Germany Gil Yosipovitch, USA
03.00 – 03.20 PM	Patient organisations Matthias Augustin, Germany
03.20 – 03.40 PM	Treat to target criteria in itch Sonja Ständer, Germany
03.40 – 04.00 PM	Working towards a modular, validated itch questionnaire Antoinette van Laarhoven, Netherlands
04.00 – 04.20 PM	Itch in atopic dermatitis: ethnic differences in the perception and quality of itch Yozo Ishiuchi, Japan
04.20 – 04.40 PM	Psychological factors in itch Christina Schut, Germany
04.40 – 05.00 PM	All: discussion
05.00 – 05.30	Break
05.30 – 05.50 PM	Opening Ceremony Saal 2 Elke Weisshaar, Germany Martin Schmelz, Germany Alexander Enk, Germany
05.50 – 06.10 PM	Bernhard Lecture Saal 2 Andreas Kremer, Switzerland
06.15 – 06.40 PM	Kuraishi Lecture Saal 2 Sarah Ross, USA
06.40 – 07.05 PM	SPECIAL INVITED LECTURE Saal 2 Atopic dermatitis: from the past to the future Kilian Eyerich, Germany
07.05 – 07.30 PM	IFSI AWARDS Saal 2
07.30	Reception

Monday 13 October 2025

07.00 – 08.00 AM **SATELLITE SYMPOSIUM | Saal 2**

07.00 – 08.00 AM **SATELLITE SYMPOSIUM | Forum**

08.00 – 09.00 AM **SESSION 1 | Saal 2**
Plenary

Chairs: Matthias Ringkamp, USA | Mitsutoshi Tominaga, Japan

08.00 – 08.20 AM **Piezo 2: more than mechanically induced itch**
Gary Lewin, Germany

08.20 – 08.40 AM **Potassium channels as antipruritic targets**
Achim Schmidtke, Germany

08.40 – 09.00 AM **Expression of pruriceptors**
Jannis Körner, Germany

09.00 – 09.45 AM **SESSION 2 | Forum**
Translational aspects of itch

Chairs: Martin Metz, Germany | Hiroyuki Murota, Japan

09.00 – 09.15 AM **Neglected dimensions: Do large language models truly grasp key quality-of-life concerns in chronic itch management?**
Ahmet Uğur Atilan, Turkey

09.15 – 09.30 AM **Broad deployment of the ItchyQuant reveals disparities in care access and follow-up in patients with itch**
Rene Chen, USA

09.30 – 09.45 AM **Dupilumab for itch on prurigo chronica multiformis: A pilot case study**
Tsukasa Ugajin, Japan

Monday 13 October 2025

09.00 – 09.45 AM **SESSION 2 | Saal 2**
Young Investigator Council Session

Chairs: Leigh Nattkemper, USA | Jürgen Solinski, Germany

The mechanisms of itch contagion
Anastasiia Myronenko, Netherlands

Role of the spinal cord in chronic itch
Miho Shiratori-Hayashi, Japan

Microbe-neuron crosstalk in itch and inflammation
Liwen Deng, USA

Periostin in Atopic Dermatitis-Associated Hypersensitivity
Josh Wheeler, USA

Social anxiety, neuroinflammation and itch in psoriasis
Marcel Schepko, Germany

Scratching Beneath the Surface: Personality and Catastrophizing in Itch Experience
Giulia Erica Aliotta, Denmark

10.00 – 10.30 **Break**

10.30 – 12.30 AM PM **SESSION 3 | Saal 2**

Clinics: New aspects and treatment concepts

Chairs: Sarina Elmariam, USA | Thomas Mettang, Germany

10.30 – 10.50 AM **CKD-aP: challenges in clinics and therapy**
Jörg Latus, Germany

10.50 – 11.10 AM **Chronic urticaria**
Petra Staubach, Germany

11.10 – 11.30 AM **Chronic prurigo**
Sonja Ständer, Germany

11.30 – 11.50 AM **Is chronic itch a public health problem? Epidemiology of chronic itch around the world**
Christian Apfelbacher, Germany

11.50 – 12.00 AM PM **Questions & Answers**

Monday 13 October 2025

10.30 – 12.00 SESSION 3 | Forum

AM PM **Research: Pathobiology of itch**
Chairs: Sarah Ross, USA | Martin Steinhoff, Qatar

10.30 – 10.50 **Spatial transcriptomics in keloids**
AM Yingrou Tan, Singapore

10.50 – 11.10 **Itch-specific neuronal clusters and druggable pathways in human DRGs**
AM Tyler Beck, USA

11.10 – 11.30 **Neurons for itch**
AM Jürgen Solinski, Germany

11.30 – 11.50 **DRG-neuron expression in atopic dogs**
AM Santosh Mishra, USA

11.50 – 12.00 **Questions & Answers**
AM PM

12.00 – 12.30 **Break**

12.30 – 01.30 LUNCH SYMPOSIUM | Saal 2

PM **Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice**
Prof. Dr. Matthias Augustin, Hamburg
Sarina Elmariah, MD, PhD, MPH, San Francisco

12.30 – 01.30 SATELLITE SYMPOSIUM | Forum

PM

01.30 – 01.45 **Break**

Monday 13 October 2025

01.45 – 02.45 SESSION 4 | Saal 2

PM **Plenary: Interesting drugs and treatment concepts**
Chairs: Ulrike Raap, Germany | Emilie Brenaut, France

01.45 – 02.05 **A pooled analysis from the RESPONSE and ENHANCE studies**
PM Andreas Kremer, Switzerland

02.05 – 02.25 **Results of the APHYAP clinical study**
PM Christelle Le Gall-Ianotto, France

02.25 – 02.45 **Guidelines on itch**
PM Elke Weisshaar, Germany
Claudia Zeidler, Germany

02.45 – 03.05 **Break**

03.05 – 04.25 SESSION 5 | Saal 2

PM **Clinics: Unmet needs in pruritus medicine**
Chairs: Suephy Chen, USA | Christian Apfelbacher, Germany

03.05 – 03.25 **Neuropathic itch**
PM Sarina Elmariah, USA

03.25 – 03.45 **Registry data**
PM Matthias Augustin, Germany

03.45 – 04.05 **Device based physical therapies**
PM Simon Müller, Switzerland

04.05 – 04.25 **Molecular pharmacological analysis of 15 psychotropic drugs in pruritus modulation: Implications for atopic dermatitis**
PM Koichi Miyakawa, Japan

03.05 – 04.25 SESSION 5 | Forum

PM **Research: Neuroimmune mechanisms**
Chairs: Xinzhong Dong, USA | Konstantin Agelopoulos, Germany

03.05 – 03.25 **The basophil-neuronal axis**
PM Fengxian Li, China

03.25 – 03.45 **Eosinophils in itch**
PM Ulrike Raap, Germany

03.45 – 04.05 **Epidermal innervation**
PM Dai Hyun Kim, South Korea

04.05 – 04.25 **Neuroimmun mechanisms in Rosacea**
PM Martin Steinhoff, Qatar

Monday 13 October 2025

04.25 – 04.40 **Break**

04.40 – 05.00 IFSI GENERAL ASSEMBLY | Saal 2

PM

05.00 – 05.30 IFSI BOARD MEETING | Saal 2

PM

06.00

SOCIAL AND DINNER

PM

Novartis-organized and funded medical symposium at WCI 2025

Itch in chronic spontaneous urticaria

Congress Centrum Heidelberg, Germany

Tuesday 14 October 2025
12:30-13:30 CEST

Symposium Room: Forum

Join **Professors Manuel Pereira** and **Martin Metz** as they explore the underlying mechanisms and management of itch in chronic spontaneous urticaria

WCI, World Congress of Itch.

This symposium is organized and funded by Novartis and is intended for an audience of non-US and non-UK HCPs within the context of the WCI Congress 2025 in Heidelberg, Germany. This presentation may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.

Global | FA-11497925 | September 2025
Copyright © 2025 Novartis Pharma AG

© Heidelberg Marketing

www.wci25.com

15

Tuesday 14 October 2025

07.00 – 08.00 AM SATELLITE SYMPOSIUM | Saal 2

08.00 – 09.00 AM SESSION 6 | Saal 2
Plenary session

Chairs: Gil Yosipovitch, USA | Gary Lewin, Germany

08.00 – 08.20 AM Inflammatory itch, a role for cytokines
Mark Hoon, USA

08.20 – 08.40 AM IgE-independent mast cell activation limits itchscratch reflex to preserve barrier integrity
Thomas Plum, Germany

08.40 – 09.00 AM Mrgpr Channels in itch: from mouse to man
Xinzhong Dong, USA

09.00 – 09.45 AM SESSION 7 | Saal 2
Best of German itch CRCs

Chairs: Bernhard Homey, Germany | Ethan Lerner, USA

09.00 – 09.15 AM Correlation of intra-epidermal nerve-fiber innervation depth with itch intensity in AD
Konstantin Agelopoulos, Germany

09.15 – 09.30 AM Integrated clinical-electrical stimulation and RNA-seq identifies a pruritus-specific gene signature in AD vs psoriasis
Peter Olah, Germany

09.30 – 09.45 AM Somatic symptom disorder: higher pruritus intensity, stress and reduced quality of life in chronic pruritus
Stefan Kahnert, Germany

Tuesday 14 October 2025

09.00 – 09.45 AM SESSION 7 | Forum
Clinics: Best of clinical trials

Chairs: Alan Fleischer, USA | Franz Legat, Austria

09.00 – 09.15 AM Pooled REMIX-1/-2 phase 3 data: Early and sustained symptom improvement with remibrutinib in chronic spontaneous urticaria
Martin Metz, Germany

09.15 – 09.30 AM Nemolizumab long-term safety and efficacy up to 104 weeks in the ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis
Matthias Augustin, Germany

09.30 – 09.45 AM Lebrikizumab provides skin clearance and itch relief at week 16 and week 52: pooled results from 2 phase 3 studies ADvocate1 and ADvocate2
Diamant Thaçi, Germany

09.45 – 10.30 Break

10.30 – 12.00 AM PM SESSION 8 | Saal 2
Clinics: Role of Psychological factors

Chairs: Laurent Misery, France | Jacek Szepietowski, Poland

10.30 – 10.50 AM Psyche and itch: new clinical and molecular findings
Eva Peters, Germany

10.50 – 11.10 AM Patient acceptance and stigmatization in psoriasis
Adam Reich, Poland

11.10 – 11.30 AM Placebo and nocebo effects in itch
Antoinette Laarhoven, Netherlands

11.30 – 11.50 AM Itch in different age groups: Relationship with psychological factors
Christina Schut, Germany

11.50 – 12.00 AM PM Questions & Answers

LUNCHTIME MEDICAL SYMPOSIUM

REDEFINING TREATMENT OUTCOMES IN PRURIGO NODULARIS: DERMATOLOGIST AND PATIENT PERSPECTIVES

Date: Tuesday, October 14, 2025, 12:30 - 1:30 PM CET

Location: World Congress on Itch 2025
Saal 2, Congress Centrum Heidelberg, Germany

CO-CHAIRS



**PROF. DR. MED. ELKE
WEISSHAAR***
Ruprecht-Karls-University
Heidelberg
Germany



**PROF. DR. MED. DR. H.C. SONJA
STÄNDER***
University of Münster
Germany

Join us at the World Congress on Itch 2025 in Heidelberg, Germany for a dynamic symposium on prurigo nodularis (PN). **Leading experts** will share the latest in itch relief, and long-term lesion management of PN, alongside a **firsthand account from a PN patient**. The session will close with a question and answer period with the faculty and a patient.

This is a must-attend event for healthcare professionals looking to advance their knowledge and care strategies. Don't miss this opportunity to stay ahead in dermatological care!

LEARNING OBJECTIVES

At the end of this program, participants will be able to:

- Recognize the **burden and complexity** of prurigo nodularis, and the significant **unmet need** of PN patients
- Appreciate the **patient journey** and the impact of disease on **quality of life**
- Understand that **itch relief** and **lasting skin healing** can be effectively and safely achieved

Tuesday 14 October 2025

10.30 – 12.00 SESSION 8 | Forum

AM PM **Research: Itch mechanisms and targets in inflammatory skin diseases**

Chairs: Mark Hoon, USA | Manuel Pereira, Germany

10.30 – 10.50 **Kappa opioids inhibit spinal circuits to suppress itch**

AM Tayler Sheahan, USA

10.50 – 11.10 **Novel findings on IL 31**

AM Bernhard Homey, Germany

11.10 – 11.30 **Parabrachial to central amygdala:**

AM **central itch neurons**

Darya Pavlenko, USA

11.30 – 11.50 **Itch mechanism in aged skin**

AM Mitsutoshi Tominaga, Japan

11.50 – 12.00 **Questions & Answers**

AM PM

12.00 – 12.30 **Break**

12.30 – 01.30 **SATELLITE SYMPOSIUM | Saal 2**

PM

12.30 – 01.30 **SATELLITE SYMPOSIUM | Forum**

PM

01.30 – 01.45 **Break**

01.45 – 02.45 SESSION 9 | Saal 2

PM **Round table: Itch and pain encoding**

Moderators:

Martin Schmelz, Germany | Earl Carstens, USA

Discussants:

Ethan Lerner, USA | Matthias Ringkamp, USA | Laurent Misery, France

01.45 – 02.05 **Specificity vs. pattern**

PM **specificity of experimental models**

02.05 – 02.25 **Terminology of chronic itch and pain**

PM

02.25 – 02.45 **Translation of itch encoding from experimental approaches to the clinics**

PM

Tuesday 14 October 2025

02.45 – 03.45 SESSION 10 | Saal 2

PM

Clinics

Chairs: Christina Schut, Germany | Adam Reich, Poland

02.45 – 03.05

PM

Chronic pruritus in older adults:

Epidemiology, associated factors, and impact on quality of life

Juliette Bollemeijer, Netherlands

03.05 – 03.25

PM

Itch in malignancy

Jacek Szepietowski, Poland

03.25 – 03.45

PM

Hematological itch

Madeline Caduc, Germany

02.45 – 03.45 SESSION 10 | Forum

PM

Clinics

Chairs: Simon Müller, Switzerland | Christelle Le Gall-Ianotto, France

02.45 – 03.05

PM

The many faces of itch in India

Asit Mittal, India

03.05 – 03.25

PM

Itching in Africa

Grace Mulyowa, Uganda

03.25 – 03.45

PM

Itching in keloids and scars

Hong Liang Tey, Singapore

03.45 – 04.15

Break



Tuesday 14 October 2025

04.15 – 05.30 SESSION 11 | Saal 2

PM

Chairs: Sonja Ständer, Germany | Elke Weisshaar, Germany

04.15 – 04.35

PM

Future perspectives in basic research of itch

Martin Schmelz, Germany

04.35 – 04.55

PM

Future perspectives in treatment of itch

Martin Metz, Germany

04.55 – 05.15

PM


Scratching the surface no more: 20 years of IFSI advancing itch research and treatment

Gil Yosipovitch, USA

05.15 – 05.30

PM

Prizes & Closing Ceremony



© Heidelberg Congress

13th World Congress on Itch

October 12-14, 2025
Congress Centrum Heidelberg
Germany



www.wci25.com

Sponsors

AbbVie Deutschland GmbH & Co. KG	8.700 €
Almirall Hermal GmbH	50.000 €
Attovia Therapeutics, Inc.	5.000 €
Beiersdorf Dermo Medical GmbH	5.000 €
Celldex Therapeutics, Inc.	5.000 €
Galderma Laboratorium GmbH	50.000 €
Lilly Deutschland GmbH	8.500 €
LEO Pharma GmbH	5.000 €
L'Oréal Deutschland GmbH	5.000 €
Mirum Pharmaceuticals Germany GmbH	5.000 €
Novartis Pharma AG	37.500 €
Sanofi and Regeneron Pharmaceuticals	60.000 €
Vifor Fresenius Medical Care Renal Pharma AG	15.500 €
Vifor Pharma Deutschland GmbH	5.000 €

© Leonhard_Niederwimmer-pixabay





Precision & Control

with **Monthly maintenance**^{†,1-8}

JOIN US

Symposium

Room: Forum
13 Oct 2025
12:30 - 13:30

ITCH IN FOCUS:

Unraveling the Neuroimmune Web of itch in Atopic Dermatitis

Prof. Dr. S. Ständer, Münster
Prof. Dr. M. Metz, Berlin

EBGLYSS[®] is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg who are candidates for systemic therapy.[†]

[†]After a 16-week Q2W induction period or once clinical response is achieved, the recommended maintenance dose of EBGLYSS[®] is 250 mg every fourth week.[†]

1. EBGLYSS[®] (lebrikizumab), EU Summary of Product Characteristics; **2.** Gonçalves F, et al. Drugs Context. 2021 Mar 30;10:2021-1-7; **3.** Bieber T. Allergy. 2020;75:54-62; **4.** Tsoi LC, et al. J Invest Dermatol. 2019 Jul;139(7):1480-1489; **5.** Yosipovitch G, et al. Br J Dermatol. 2024 Jan 23;190(2):289-291; **6.** Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091; **7.** Blauvelt A, et al. Br J Dermatol. 2023 May 24;188(6):740-748. **8.** Thaçi D, et al. Efficacy and Safety of Lebrikizumab Is Maintained Up to 3 Years in Patients With Moderate-to-Severe Atopic Dermatitis: ADvocate 1 and ADvocate 2 to ADjoin Long-Term Extension Trial. Presented at the European Academy of Dermatology and Venereology (EADV) ; Amsterdam, Netherlands; September 25-28, 2024. DIT01.2.

Ebglyss[®] 250mg Injektionslösung in einer Fertigspritze
Ebglyss[®] 250 mg Injektionslösung im Fertigpen

▼ **Zusammensetzung:** Sowohl **1 Ebglyss Fertigspritze** als auch **1 Ebglyss Fertigpen** enthalten jeweils **Wirkstoff:** 250 mg Lebrikizumab in 2 ml Lösung. **Sonstige Bestandteile:** Histidin, Essigsäure 99%, Saccharose, Polysorbat 20, Wasser für Injektionszwecke. Lebrikizumab wird mittels rekombinanter DNA-Technologie in Ovarialzellen des chinesischen Hamsters (CHO-Zellen) hergestellt. **Anwendungsgebiete:** Behandlung von mittelschwerer bis schwerer atopischer Dermatitis bei Erwachsenen und Jugendlichen ab 12 Jahren mit einem Körpergewicht von mindestens 40 kg, die für eine systemische Therapie in Betracht kommen. **Gegenanzeigen:** Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile. **Nebenwirkungen:** **Häufig:** Konjunktivitis, Trockenes Auge, allergische Konjunktivitis, Reaktionen an der Injektionsstelle; **Gelegentlich:** Herpes zoster, Eosinophilie, Keratitis, Blepharitis. Verschreibungspflichtig. **Stand:** März 2025

Almirall, S.A., Ronda General Mitre, 151, 08022 Barcelona, Spanien • Örtlicher Vertreter: Almirall Hermal GmbH • D-21462 Reinbek • www.almirall.de • info@almirall.de